- 客服:
- 电话: 13061953619
- 微信:
Mal-(CH2)5-Val-Cit-PAB-Eribulin 是抗体偶联药物的一部分 (drug-linker conjugate for ADC),具有抗癌活性,它由抗微管剂Eribulin 和linker Mal-(CH2)5-Val-Cit-PAB 组成。
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB[1].
Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules[2].
[1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. Patent US20170252458A1.
[2]. Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10(2): 161-174.
动态评分
0.0